An Open-label, 3-Part, Multiple Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-5172.
Phase of Trial: Phase I
Latest Information Update: 25 Sep 2017
At a glance
- Drugs Grazoprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 25 Sep 2017 Results published in the Antimicrobial Agents and Chemotherapy
- 03 Feb 2016 According to ClinicalTrials.gov record,primary end points has been revised also study design changed from randomised to non-randomised.
- 30 Sep 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.